CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Revenue of CureVac N.V. (CVAC)
Revenue in 2023 (TTM): $53.76 M
According to CureVac N.V.'s latest financial reports the company's current revenue (TTM) is $53.76 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of CureVac N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $53.76 M | $-70,608,000 | $-234,090,000 | $-259,969,000 | $-260,167,000 |
| 2022 | $67.42 M | $-116,573,000 | $-209,386,000 | $-249,155,000 | $-249,029,000 |
| 2021 | $102.99 M | $-135,205,000 | $-386,486,000 | $-412,498,000 | $-411,716,000 |
| 2020 | $48.9 M | $34.73 M | $-123,095,000 | $-129,800,000 | $-129,074,000 |
| 2019 | $17.42 M | $-10,567,000 | $-91,501,000 | $-100,125,000 | $-99,873,000 |
| 2018 | $12.87 M | $-4,873,000 | $-69,851,000 | $-71,131,000 | $-71,241,000 |